All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

Product Type

Companies

Bavarian Nordic

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Bavarian Nordic to Manufacture Additional Ebola Vaccines for Janssen

Lead Product(s): MVA-BN Filo vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-BN-Filo

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Janssen Pharmaceutical

Deal Size: $13.9 million Upfront Cash: Undisclosed

Deal Type: Agreement June 18, 2020

Details:

Bavarian Nordic will manufacture and deliver bulk drug substance of its MVA-BN Filo vaccine, which Janssen has licensed as part of its Ebola vaccine regimen.